Veradigm (MDRX)
Market Price (5/3/2026): $0 | Market Cap: $0Sector: Health Care | Industry: Health Care Technology
Veradigm (MDRX)
Market Price (5/3/2026): $0Market Cap: $0Sector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% Attractive yieldFCF Yield is 16% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, AI in Healthcare Management, and Telehealth Platforms. | Weak multi-year price returns2Y Excs Rtn is -83%, 3Y Excs Rtn is -140% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -20%, Rev Chg QQuarterly Revenue Change % is -9.7% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% Key risksMDRX key risks include [1] potential delisting from Nasdaq resulting from [2] its failure to file required financial reports, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Attractive yieldFCF Yield is 16% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, AI in Healthcare Management, and Telehealth Platforms. |
| Weak multi-year price returns2Y Excs Rtn is -83%, 3Y Excs Rtn is -140% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -20%, Rev Chg QQuarterly Revenue Change % is -9.7% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksMDRX key risks include [1] potential delisting from Nasdaq resulting from [2] its failure to file required financial reports, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Resolution of SEC Investigation Provides Stability Amidst Continued Delisting.
Veradigm's stock remained largely stable following the formal closure of the U.S. Securities and Exchange Commission (SEC) investigation on February 20, 2026. This removed a significant regulatory overhang that had previously contributed to uncertainty around the company's financial reporting and internal controls. However, the stock continues to trade on the OTC market at levels near its 20-year lows, as the company is still working to become current with its 2023 and 2024 Annual Reports on Form 10-K, which are expected to be filed around May 11, 2026, with an aim for relisting on Nasdaq by the end of 2026.
2. Flat Revenue Outlook and Decreased Cash Position.
The company's estimated financial performance for fiscal year 2025, provided on February 17, 2026, indicated revenue was approximately flat with 2024, ranging between $584 million and $589 million (down 1% at the mid-point compared to 2024). Additionally, cash and equivalents decreased by $174 million in 2025, reaching $120 million as of December 31, 2025, primarily due to net outflows from debt financing activities. This largely flat revenue trajectory and a reduction in cash likely dampened significant positive momentum.
Show more
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
1/31/2026 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MDRX | -1.3% | |
| Market (SPY) | 3.6% | -5.3% |
| Sector (XLV) | -5.8% | 2.3% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MDRX | -2.1% | |
| Market (SPY) | 5.5% | -11.7% |
| Sector (XLV) | 1.5% | 6.7% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MDRX | 10.6% | |
| Market (SPY) | 30.4% | -10.4% |
| Sector (XLV) | 5.2% | -3.7% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MDRX | -62.4% | |
| Market (SPY) | 78.7% | 6.3% |
| Sector (XLV) | 14.3% | 4.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDRX Return | 28% | -4% | -41% | -7% | -51% | -2% | -67% |
| Peers Return | 35% | -35% | 13% | 15% | 9% | -22% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| MDRX Win Rate | 58% | 42% | 33% | 50% | 33% | 50% | |
| Peers Win Rate | 63% | 33% | 50% | 47% | 52% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MDRX Max Drawdown | -9% | -25% | -46% | -43% | -60% | -12% | |
| Peers Max Drawdown | -6% | -46% | -12% | -14% | -25% | -30% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ORCL, IQV, VEEV, GEHC, OMCL. See MDRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | MDRX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -25.6% | -24.5% |
| % Gain to Breakeven | 34.4% | 32.4% |
| Time to Breakeven | 49 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.2% | -33.7% |
| % Gain to Breakeven | 73.1% | 50.9% |
| Time to Breakeven | 136 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.8% | -19.2% |
| % Gain to Breakeven | 60.6% | 23.7% |
| Time to Breakeven | 701 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -24.1% | -3.7% |
| % Gain to Breakeven | 31.7% | 3.9% |
| Time to Breakeven | 270 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.2% | -12.2% |
| % Gain to Breakeven | 17.9% | 13.9% |
| Time to Breakeven | 176 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -24.0% | -6.8% |
| % Gain to Breakeven | 31.6% | 7.3% |
| Time to Breakeven | 248 days | 15 days |
In The Past
Veradigm's stock fell -8.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MDRX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -25.6% | -24.5% |
| % Gain to Breakeven | 34.4% | 32.4% |
| Time to Breakeven | 49 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.2% | -33.7% |
| % Gain to Breakeven | 73.1% | 50.9% |
| Time to Breakeven | 136 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.8% | -19.2% |
| % Gain to Breakeven | 60.6% | 23.7% |
| Time to Breakeven | 701 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -24.1% | -3.7% |
| % Gain to Breakeven | 31.7% | 3.9% |
| Time to Breakeven | 270 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -24.0% | -6.8% |
| % Gain to Breakeven | 31.6% | 7.3% |
| Time to Breakeven | 248 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -23.5% | -17.9% |
| % Gain to Breakeven | 30.6% | 21.8% |
| Time to Breakeven | 41 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -26.6% | -15.4% |
| % Gain to Breakeven | 36.3% | 18.2% |
| Time to Breakeven | 220 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -56.3% | -53.4% |
| % Gain to Breakeven | 128.7% | 114.4% |
| Time to Breakeven | 373 days | 1085 days |
In The Past
Veradigm's stock fell -8.8% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Veradigm (MDRX)
AI Analysis | Feedback
The Salesforce.com of the healthcare world, providing a comprehensive suite of software and data solutions for doctors, hospitals, insurance companies, and pharmaceutical firms.
A competitor to Oracle Health (formerly Cerner) or Epic Systems, offering electronic health records and related IT services to healthcare providers.
AI Analysis | Feedback
- Electronic Health Records (EHR) Software: Provides integrated clinical and financial management software for healthcare providers of all sizes.
- Payer and Life Sciences Solutions: Offers specialized data and software solutions tailored for health plans, life sciences companies, and other healthcare stakeholders.
- Healthcare Analytics & Population Health Management: Delivers tools and services for analyzing health data to improve patient outcomes and manage population health.
- Information Connectivity Solutions: Facilitates secure and efficient exchange of healthcare information among providers, patients, and other systems.
- Healthcare IT Services & Support: Provides comprehensive services including private cloud hosting, implementation, maintenance, and revenue cycle management for healthcare organizations.
- Patient Engagement Software: Develops applications designed to enhance patient interaction and involvement in their personal healthcare journey.
AI Analysis | Feedback
Major Customers of Veradigm (MDRX)
Veradigm Inc. primarily sells its information technology solutions and services to other companies and organizations within the healthcare industry. Based on the company description, its major customer categories include:
- Hospitals, Health Systems, and Physician Practices: This category encompasses a broad range of healthcare providers, from large hospitals and health systems to single-specialty, small, and mid-sized physician practices. Veradigm provides them with electronic health records (EHR), clinical and financial management solutions, and related services.
- Payers, Health Plans, and Insurance Companies: Veradigm targets these entities with its payer solutions, which include services for health plans, insurance companies, and pharmacy benefit managers.
- Life Sciences Companies: The company offers specific solutions designed for life sciences organizations.
- Government and Other Healthcare Organizations: This diverse category includes governments and militaries, retail clinics, surgery centers, retail pharmacies, employer wellness clinics, lab companies, urgent care facilities, and post-acute organizations.
AI Analysis | Feedback
Microsoft (MSFT)
AI Analysis | Feedback
Don Trigg, Chief Executive Officer
Don Trigg is a healthcare technology veteran with over two decades of experience. Before joining Veradigm, he served as CEO of apree health, where he leveraged data and technology to scale a multi-state, next-generation advanced primary care model. Apree health was acquired by Elevance Health in 2024. Prior to apree health, Mr. Trigg was President of healthcare IT innovator Cerner Corporation, overseeing its electronic medical record, revenue cycle, and strategic growth businesses.
Lee Westerfield, Interim Chief Financial Officer
Mr. Westerfield has held multiple Chief Financial Officer roles in sectors undergoing dynamic change and has scaled, funded, and exited several software and data service-based ventures. He most recently served as Chief Financial Officer of Clearsense, an enterprise healthcare data analytics platform, and as CFO of Aetion, a real-world evidence company. He also held CFO positions at Dstillery, an advertising technology data analytics provider, and Uphold, a financial technology platform as a service company, where he later served as Vice Chairman of the Board of Directors.
Tehsin Syed, Chief Product and Technology Officer
Tehsin Syed serves as the Chief Product and Technology Officer at Veradigm. Further detailed background information on specific prior company management, sales, or private equity involvement was not readily available in the provided search results.
Jay Bhattacharyya, SVP & General Manager of Veradigm Payer
Jay Bhattacharyya has served as Senior Vice President and General Manager of Veradigm Payer since August 2020. He previously held roles within the company as Chief Strategy Officer and Senior Vice President, and Chief Operating Officer for Payer & Life Sciences. Prior to joining Veradigm, Mr. Bhattacharyya was the Co-Founder & Chief Financial Officer of Empire Communications. He also worked as a financial analyst at The Cigna Group.
Troy Tetzlaff, SVP Revenue Operations
Troy Tetzlaff is an accomplished executive with over 20 years of experience in transforming organizations, scaling high-performing teams, and driving revenue growth in technology, healthcare, and SaaS markets. Before Veradigm, he spent five years as CEO for FanThreeSixty (FTS), a sports and entertainment IT analytics company, where he led a comprehensive company transformation and growth period. He also gained extensive experience in business strategy, engineering, product development, and client services during his 15 years at Cerner.
AI Analysis | Feedback
Here are the key risks to Veradigm (MDRX):
-
Financial Reporting Deficiencies and Nasdaq Delisting
Veradigm faces significant ongoing risks related to its financial reporting. The company has a history of internal control failures that led to misstatements in previously issued financial statements, requiring extensive restatements and audits for fiscal years 2020, 2021, and 2022. These deficiencies resulted in substantial delays in SEC filings, including annual and quarterly reports, and ultimately led to the company's delisting from Nasdaq in February 2024. Veradigm is actively working to become current with its SEC filings, with a target of 2026, to pursue relisting on a national securities exchange. This situation impacts investor confidence, limits access to capital, and incurs significant accounting and legal costs.
-
Intense Market Competition and Customer Attrition
Veradigm operates in a fiercely competitive healthcare technology sector, contending with major players such as Epic and Oracle Health in the EHR space, and specialized firms like IQVIA and Definitive Healthcare in data analytics and life sciences. This intense competition has contributed to customer attrition, particularly among large physician practices, and delays in clinical data project implementations have affected the company's revenue forecasts.
-
Regulatory Compliance, Litigation, and Data Security Risks
As a healthcare technology company, Veradigm operates in a highly regulated industry, making it vulnerable to risks from evolving healthcare laws and regulations. Changes in these regulations could increase compliance costs and impact the marketability of its products. Furthermore, the company is subject to ongoing SEC investigations and stockholder litigation related to its financial disclosures, which could lead to significant legal expenses and potential damages. The company has also experienced data security incidents, such as a data breach in late 2024 affecting several customers due to credential theft, highlighting the continuous need for robust data security measures to protect sensitive patient information.
AI Analysis | Feedback
The increasing aggressive entry and expansion of large, well-resourced technology companies (e.g., Amazon, Microsoft, Google, Apple) into the healthcare IT and services sector poses a clear emerging threat. These companies leverage their vast cloud infrastructure, advanced AI/ML capabilities, and strong consumer-facing brands to offer integrated solutions that could potentially disrupt traditional healthcare technology providers like Veradigm. Their offerings often include areas directly competing with Veradigm's segments, such as patient engagement, data analytics, cloud hosting for healthcare, and even direct patient care models (e.g., Amazon One Medical, Amazon Pharmacy, Microsoft's Nuance acquisition and Azure Health Data Services, Google's Verily and AI health initiatives). These tech giants possess the capital, talent, and technological edge to rapidly innovate and capture market share, potentially making existing solutions seem less agile or comprehensive.
AI Analysis | Feedback
Veradigm (MDRX) operates in several significant addressable markets within the healthcare technology sector. The market sizes for its main products and services vary by region, primarily the U.S. and global markets.
Electronic Health Records (EHR)
- The global electronic health records market size was estimated at approximately USD 35.89 billion in 2025 and is projected to reach USD 53.11 billion by 2033, growing at a CAGR of 5.10% from 2026 to 2033. Other estimates place the global market at USD 36.8 billion in 2026, reaching USD 57.9 billion by 2033 with a CAGR of 6.7%. Another source indicates a global market size of USD 33.99 billion in 2026, growing to USD 52.60 billion by 2034 with a CAGR of 5.61%.
- The U.S. electronic health records market size was USD 13.7 billion in 2023 and is expected to grow rapidly through 2032. The U.S. market for hospital EHRs specifically generated USD 6,890.6 million in 2023 and is expected to reach USD 7,815.0 million by 2030, with a CAGR of 1.8% from 2024 to 2030. The U.S. market is projected to reach USD 15.02 billion by 2026.
Population Health Management
- The global population health management market size was valued at USD 41.84 billion in 2025. It is projected to grow from USD 47.69 billion in 2026 to USD 189.13 billion by 2034, exhibiting a CAGR of 18.79%. Other sources estimate the global market at USD 101.0 billion in 2025, reaching USD 371.4 billion by 2034 at a CAGR of 15.11% from 2026 to 2034. Another projection shows the global market at USD 71.24 billion in 2025, growing to USD 189.79 billion in 2030 at a CAGR of 21.6%.
- North America is a dominant region, holding a 65.90% share in 2025, with the U.S. market valued at USD 27.52 billion by 2026. The U.S. population health management market size was estimated at USD 36.04 billion in 2024 and is projected to reach USD 210.18 billion by 2033, growing at a CAGR of 21.70% from 2025 to 2033.
Healthcare Analytics
- The global healthcare analytics market size was valued at USD 13.44 million in 2023 and is projected to reach USD 50.92 million by 2032, with an expected CAGR of 20.96%. Another estimate states the global market size was USD 30.33 billion in 2025 and is projected to grow from USD 36.03 billion in 2026 to USD 262.52 billion by 2034, exhibiting a CAGR of 28.18%. Other figures indicate a global market size of USD 55.99 billion in 2026, expected to reach USD 217.59 billion by 2033 with a CAGR of 21.4% from 2026 to 2033. Another source mentions the global market size was USD 64.49 billion in 2025, predicted to increase from USD 78.30 billion in 2026 to approximately USD 369.66 billion by 2034, expanding at a CAGR of 21.41% from 2025 to 2034.
- North America led the global healthcare analytics market with a market share of 49.03% in 2025. The U.S. healthcare analytics market size was estimated at USD 21.21 billion in 2024 and is projected to reach USD 67.48 billion by 2033, growing at a CAGR of 12.76% from 2025 to 2033. Another estimate for the U.S. market generated a revenue of USD 13,869.4 million in 2024 and is expected to reach USD 44,132.6 million by 2033, growing at a CAGR of 12.8% from 2025 to 2033. The U.S. healthcare big data analytics market was valued at USD 24.7 billion in 2025 and is projected to reach USD 62.43 billion by 2034, growing at a CAGR of 10.9% from 2026-2034.
Payer Solutions
- The global healthcare payer solutions market size was valued at USD 72.19 billion in 2024 and is expected to reach USD 133.63 billion by 2032, at a CAGR of 8.00%. Other data indicates the global healthcare payer services market size was estimated at USD 71.76 billion in 2024 and is predicted to increase from USD 76.85 billion in 2025 to approximately USD 141.47 billion by 2034, expanding at a CAGR of 7.02% from 2025 to 2034.
- The U.S. healthcare payer solutions market held the largest revenue share of 78.6% in North America in 2024. The healthcare payer services market in the United States is expected to reach a projected revenue of US$ 66,695.2 million by 2030, growing at a CAGR of 7.4% from 2024 to 2030. The U.S. healthcare payer services market size was estimated at USD 38.23 billion in 2024 and is expected to reach over USD 75.91 billion by 2034, expanding at a CAGR of 7.10% from 2025 to 2034.
Life Sciences Solutions
- The global life science market size is calculated at US$ 88.2 billion in 2024, grew to US$ 98.63 billion in 2025, and is projected to reach around US$ 269.56 billion by 2034, expanding at a CAGR of 11.82% between 2025 and 2034. The global life sciences IT market size is projected to reach USD 67.69 billion by 2034, growing at a CAGR of 11.06% from 2025 to 2034. The global life sciences software market size was valued at USD 16.51 billion in 2024 and is poised to grow from USD 18.54 billion in 2025 to USD 46.89 billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026–2033).
- The U.S. life science tools market size was estimated at USD 56.61 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2024 to 2030. The North American life science market is set to grow from US$ 39.25 billion in 2025 to US$ 110.75 billion by 2034 at a 12.08% CAGR.
Revenue Cycle Management (RCM)
- The global Revenue Cycle Management (RCM) market grew from USD 112.89 billion in 2025 to USD 121.24 billion in 2026 and is expected to reach USD 191.38 billion by 2032, reflecting a CAGR of 7.83%. Another report indicates the global market size was valued at USD 163.72 billion in 2025 and is projected to grow from USD 180.91 billion in 2026 to USD 472.42 billion by 2034, exhibiting a CAGR of 12.70%. Another estimate places the global revenue cycle management market size at USD 169.69 billion in 2025, anticipated to reach around USD 451.29 billion by 2034, expanding at a CAGR of 11.50% from 2025 to 2034.
- North America dominated the global market with the largest market share of 55% in 2025. The Revenue Cycle Management (RCM) market in the U.S. is projected to reach USD 65 billion by 2026, expanding at a CAGR of 7.5% from 2021. The U.S. revenue cycle management market size is expected to see growth from USD 72.97 billion in 2026 to USD 195.92 billion by 2035, expanding at a CAGR of 11.6%. Another source states the U.S. Revenue Cycle Management Market was valued at USD 141.61 billion in 2024, and is expected to reach USD 272.78 billion by 2030, rising at a CAGR of 11.55%.
AI Analysis | Feedback
Veradigm Inc. (MDRX) is focusing on several key drivers to reignite and grow its revenue over the next two to three years, despite some analyst forecasts for overall flat or declining revenue during this period. These strategic initiatives center on enhancing its core offerings, leveraging technology, and expanding into high-growth areas within the healthcare ecosystem.
Expected drivers of future revenue growth for Veradigm include:
- Expansion of the Provider Base and EHR Network with a focus on High-Value Specialty Practices: Veradigm's growth strategy emphasizes expanding its core provider base and enhancing the value of its offerings by integrating high-value specialty practices into its Electronic Health Records (EHR) network. This expansion aims to strengthen its foundation in the healthcare ecosystem, which in turn supports the growth of its payer and life sciences solutions.
- Advancement and Adoption of AI-Enabled Solutions: The company is strategically investing in and advancing AI-enabled clinical and financial workflows. Recent developments include the launch of new AI applications for revenue cycle insights for independent practices and enhancements to its AI-enabled ambient scribe solution. Veradigm projects its AI analytics unit to generate significant revenue, highlighting the importance of artificial intelligence in its growth strategy.
- Broadening Revenue Cycle Management (RCM) Solutions: Veradigm is committed to broadening its reach and offerings in revenue cycle management solutions. This includes focusing on the growth potential within its underpenetrated revenue cycle services. The company has secured new agreements with large healthcare organizations for its practice management and revenue cycle analytics solutions, indicating traction in this area.
- Growth in Payer and Life Sciences Solutions, particularly Data Analytics and Clinical Data Exchange: The Payer and Life Sciences segment is identified as a key growth area for Veradigm. The company aims for its data analytics and life sciences services to account for over 50% of total revenue by 2027, a substantial increase from approximately 35% in 2024. Initiatives such as increasing revenue from clinical data exchange and gap closure products, along with the planned launch of a 'Clinical Trials Network' in 2025, are designed to deepen engagement with life sciences partners and fuel growth in this segment.
AI Analysis | Feedback
Share Repurchases
- Veradigm approved a new share repurchase program of up to $250 million in January 2023, replacing a previous authorization that was almost fully utilized.
- In 2022, Veradigm repurchased $234 million of its common stock.
Share Issuance
- As of December 31, 2025, Veradigm had 108.8 million basic shares of common stock outstanding.
- As of December 31, 2025, 11.6 million unvested restricted stock units (RSUs) were outstanding, issued to incentivize employees.
Inbound Investments
- Veradigm secured $100 million in new debt financing, with $75 million drawn by March 31, 2025.
- In Q2 2025, the company saw approximately $72 million of net inflows from debt financing.
Outbound Investments
- The company reported $14 million in outflows for prior acquisitions in 2025.
- Veradigm had net outflows for equity investments of $59 million in 2023.
- Outflows for acquisitions amounted to $110 million in 2024.
Capital Expenditures
- Capital expenditures were $32 million in 2025, primarily focused on software development.
- The company's capital expenditures were $35 million in 2024.
- Veradigm recorded $30 million in capital expenditures during 2023.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MDRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 109.40 |
| Mkt Cap | 27.3 |
| Rev LTM | 9,753 |
| Op Inc LTM | 1,602 |
| FCF LTM | 749 |
| FCF 3Y Avg | 624 |
| CFO LTM | 1,721 |
| CFO 3Y Avg | 1,546 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 4.1% |
| Rev Chg Q | 8.8% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 8.7% |
| Op Inc Chg 3Y Avg | 21.4% |
| Op Mgn LTM | 13.3% |
| Op Mgn 3Y Avg | 13.5% |
| QoQ Delta Op Mgn LTM | -0.5% |
| CFO/Rev LTM | 18.0% |
| CFO/Rev 3Y Avg | 15.3% |
| FCF/Rev LTM | 9.9% |
| FCF/Rev 3Y Avg | 8.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 27.3 |
| P/S | 1.6 |
| P/Op Inc | 17.8 |
| P/EBIT | 16.8 |
| P/E | 25.1 |
| P/CFO | 14.4 |
| Total Yield | 3.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.7% |
| D/E | 0.3 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.4% |
| 3M Rtn | -13.8% |
| 6M Rtn | -22.8% |
| 12M Rtn | 4.8% |
| 3Y Rtn | -19.3% |
| 1M Excs Rtn | -8.8% |
| 3M Excs Rtn | -18.0% |
| 6M Excs Rtn | -29.2% |
| 12M Excs Rtn | -23.7% |
| 3Y Excs Rtn | -98.4% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2022 | 2021 | 2020 |
|---|---|---|---|
| Legacy Veradigm | 549 | 525 | |
| Unallocated Amounts | 29 | 31 | -7 |
| Core Clinical and Financial Solutions | 1,377 | ||
| Data, Analytics and Care Coordination | 263 | ||
| Total | 577 | 556 | 1,633 |
| $ Mil | 2022 | 2021 | 2020 |
|---|---|---|---|
| Legacy Veradigm | 70 | 19 | |
| Unallocated Amounts | 7 | -11 | |
| Core Clinical and Financial Solutions | -80 | ||
| Data, Analytics and Care Coordination | -19 | ||
| Total | 77 | 8 | -100 |
Price Behavior
| Market Price | $4.70 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 07/26/1999 | |
| Distance from 52W High | -10.5% | |
| 50 Days | 200 Days | |
| DMA Price | $5.02 | $7.28 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -6.4% | -35.4% |
| 3M | 1YR | |
| Volatility | 64.9% | 59.4% |
| Downside Capture | -0.83 | -0.41 |
| Upside Capture | -100.50 | -29.11 |
| Correlation (SPY) | -5.3% | -9.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.61 | -0.18 | -0.18 | -0.41 | -0.41 | 0.21 |
| Up Beta | 0.54 | 0.99 | 0.98 | 0.08 | -0.22 | 0.30 |
| Down Beta | 7.90 | 1.09 | 0.50 | -0.77 | -1.14 | 0.05 |
| Up Capture | -82% | -99% | -81% | -41% | -9% | -0% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 9 | 17 | 23 | 40 | 82 | 313 |
| Down Capture | -663% | -83% | -72% | -48% | -38% | 74% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 18 | 27 | 40 | 79 | 315 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDRX | |
|---|---|---|---|---|
| MDRX | 25.3% | 58.1% | 0.79 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | -7.9% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | -12.8% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | 2.6% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | -3.5% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | -13.5% |
| Bitcoin (BTCUSD) | -17.1% | 42.2% | -0.33 | -17.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDRX | |
|---|---|---|---|---|
| MDRX | -19.9% | 47.0% | -0.34 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | 14.8% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 18.8% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 5.2% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 6.6% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | 17.9% |
| Bitcoin (BTCUSD) | 7.7% | 56.2% | 0.35 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDRX | |
|---|---|---|---|---|
| MDRX | -9.2% | 45.2% | -0.05 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 29.0% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 33.7% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 2.3% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 13.3% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 29.4% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 9.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/17/2026 | 4.7% | 0.0% | 8.1% |
| 9/30/2025 | -2.1% | -2.1% | 0.0% |
| 6/23/2025 | 0.2% | 4.7% | 7.6% |
| 3/18/2025 | -8.9% | -17.0% | -16.8% |
| 2/27/2024 | -8.5% | -23.0% | -6.0% |
| 1/10/2024 | -12.4% | -17.2% | -21.0% |
| 9/18/2023 | 7.0% | 3.4% | 10.6% |
| 2/28/2023 | -12.8% | -13.2% | -21.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 10 |
| # Negative | 8 | 9 | 8 |
| Median Positive | 6.8% | 8.4% | 12.2% |
| Median Negative | -7.4% | -10.2% | -11.8% |
| Max Positive | 16.0% | 32.7% | 34.5% |
| Max Negative | -12.8% | -23.0% | -21.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2022 | 03/18/2025 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 04/30/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 10/30/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
| 03/31/2019 | 05/03/2019 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.